

# Real-Time Quantitative PCR Assay Data Analysis, Evaluation and Optimization

#### A Tutorial

on

Quantification Assay Analysis and Evaluation and

Trouble-Shooting Sub-Optimal Real-Time QPCR Experiments

by

Rainer B. Lanz, M.S., Ph.D. February 20. 2009







- · Introduction:
  - Real-time QPCR & Amplification Efficiency,
  - Mathematics of QPCR
- Data Analysis and Evaluation:
  - Quantification Strategies in QPCR
    - · Absolute Quantification
    - Relative Quantification: Standard curve method Comparative CT method
  - Fidelity in QPCR
    - Specificity, Sensitivity, Accuracy, Reproducibility
    - · Experimental Variations, Replicates,
    - · Standard Deviation Calculations
- Optimizing QPCR experiments
  - Primer and probe optimization
  - Multiplex assay optimization

#### Essentials - One More Time

- Target Reporter Fluorescence...
  - is determined from the fractional cycle at which a threshold amount of amplicon DNA is reached:
    - $R_{CT} = R_0 \cdot (1 + E_T)^{CT}$
  - Amplification Efficiency (@ threshold T):  $E_T = 10^{(-1/s)} 1$ 
    - slope (s) of linear regression of  $C_T$  values vs. log[cDNA]
  - Fluorescence increase I is proportional to the amount of target DNA:  $I = k \cdot R_{CT}$





# Mathematics of QPCR



$$- R_{CT} = R_0 \cdot (1 + E_T)^{CT}$$


- Taking the logarithm yields:  $log(R_{CT}) = log(R_0) + log(1+E) \cdot C_T$
- rearrangement:  $C_T = \log(R_{CT})/\log(1+E) \log(R_o)/\log(1+E)$ , or:  $C_T = -1/\log(1+E) \cdot \log(R_o) + \log(R_{CT})/\log(1+E)$



$$s = -1/\log(1+E)$$
, or:  $\log(1+E) = -1/s$ 

• Solving the logarithm then yields the amplification efficiency:  $1+E = 10^{-1/s}$ .  $E = 10^{(-1/s)}-1$ 

[for E=1: 
$$2 = 10^{-1/s}$$
, or  $\log 2 = -1/s$ , or:  $s = -1/\log 2 = -3.32$ ]



- Because we aim at obtaining the initial numbers of target molecules, it is appropriate to now substitute reporter fluorescence R with numbers N:

• 
$$N_0 = N_{CT}/(1+E)^{CT}$$
 (I) and I = k  $N_{CT}$ 



- Absolute Quantification
  - Absolute Standard Curve Method > requires standards of known quantities
    - STND<sub>1/2/ ./6</sub>, UNKN, NTC
- Relative Quantification
  - A comparative method: requires a reference, which is also a target (2<sup>nd</sup> amlicon), = active reference.
  - Relative Standard Curve Method: relative target quantity in relation to standard curves of standard and reference
    - STND<sub>1, 2, ..., 6</sub>, REF<sub>1, 2, ..., 6</sub>, UNKN, NTC
  - Comparative  $C_T$  Method ( $\Delta\Delta C_T$ ): relative target quantity in relation to a endogenous control only (no standards)
    - · REF, UNKN, NTC

# Absolute Quantification: AQ

- A Calibration Curve Method
  - Known amounts of external targets are amplified in a parallel group of reactions run under identical conditions to that of the unknown samples.
  - Standards: recRNA, recDNA, gDNA
  - The absolute quantities of the standards must first be determined by some other independent means.
  - SDS determines  $N_0$  for each Unknown based on linear regression calculations of the standards.



#### AQ ... continued

No Data Munching

Quantities exported

· to Excel

 to text only calculated on the basis of a calibration curve (standard curve).

Easy, but ...

- Standards

DNA: appropriate?

· RNA: different RT

- Expensive

- Least accurate method

quantitative accuracy = f(standards, RT, standard curve)

20	Standard	Curve						
21	-3.36	18.646	0.997	0.11	(3, 14)			
22								
23	Sample In	formation						
24	Well	Туре	Sample	Replicate	Ct	Quantity	Std. Dev.	Mean
	A4	UNKN	A4	1	18.89	8.50E-01	0.06	0.88
26	A5	UNKN	A5	1	18.9	8.40E-01	0.06	0.88
27	A6	UNKN	A6	1	18.72	9.50E-01	0.06	0.88
	C7	UNKN	C7	10	21.19	1.80E-01	0.01	0.19
29	C8	UNKN	C8	10	21.1	1.90E-01	0.01	0.19
	C9	UNKN	C9	10	21.04	1.90E-01	0.01	0.19
31	C10	UNKN	C10	11	24.99	1.30E-02	0	0.01
32	C11	UNKN	C11	11	25.06	1.20E-02	0	0.01
33	C12	UNKN	C12	11	25	1.30E-02	0	0.01
34	A7	UNKN	A7	2	22.57	6.80E-02	0.01	0.06
35	A8	UNKN	A8	2	22.82	5.70E-02	0.01	0.06
36	A9	UNKN	A9	2	22.62	6.50E-02	0.01	0.06
37	A10	UNKN	A10	3	19.49	5.60E-01	0.03	0.57
	A11	UNKN	A11	3	19.54	5.40E-01	0.03	0.57
39	A12	UNKN	A12	3	19.39	6.00E-01	0.03	0.57
40	B1	UNKN	B1	4	19.35	5.80E-01	0.03	0.57
41	B2	UNKN	B2	4	19.58	5.30E-01	0.04	0.57
42	B3	UNKN	B3	4	19.38	6.00E-01	0.04	0.57
43	B4	UNKN	B4	5	23.02	5.00E-01	0.04	0.05
44	B5	UNKN	B5	5	23.02	4.90E-02	0	0.05
45	B6	UNKN	B6	5	23.03	5.00E-02	0	0.05
46	B7	UNKN	B7	6	20.99	2.00E-01	0.01	0.22
47	B8	UNKN	B8	6	20.99	The second second second	0.01	0.22
48	B9	UNKN	B9	6	20.82	2.20E-01 2.20E-01	0.01	0.22
				9	20.83			
49 50	B10	UNKN	B10	7	20.83	2.20E-01	0.02	0.23
	B11 B12	UNKN	B11	7		2.20E-01	0.02	0.23
51	C1	UNKN	B12	8	20.65	2.50E-01	0.02	0.23
	- Contract C	UNKN	C1	8	25.06	1.20E-02	0	0.01
	C2	UNKN	C2	8	24.89	1.40E-02	0	0.01
54	C3	UNKN	C3	8	24.83	1.40E-02	0	0.01
55	C4	UNKN	C4	9	21.15	1.80E-01	0.01	0.18
56	C5	UNKN	C5		21.03	2.00E-01	0.01	0.18
57	C6	UNKN	C6	NT/C	21.17	1.80E-01	0.01	0.18
58	D10	NTC	D10		37 81	1.005.00	0	0
59	A1	STND	A1	s1	18.43	1.00E+00	0	1
60	A2	STND	A2	s1	18.86	1.00E+00	0	1
61	A3	STND	A3	s1	18.85	1.00E+00	0	1
62	D1	STND	D1	s2	22.07	1.00E-01	0	0.1
63	D2	STND	D2	s2	22.05	1.00E-01	0	0.1
64	D3	STND	D3	s2	21.73		0	0.1
65	D4	STND	D4	s3	25.19	1.00E-02	0	0.01
66	D5	STND	D5	s3	25.23	1.00E-02	0	0.01
67	D6	STND	D6	s3	25.39	1.00E-02	0	0.01
68	D7	STND	D7	s4	28.4	1.00E-03	0	0
69	D8	STND	D8	s4	29	1.00E-03	0	0
70	D9	STND	D9	s4	29.01	1.00E-03	0	0
71								






- ...is used to determine changes in the amount of a given sample *relative* to another -internal control sample.
  - a different amplicon in the same PCR reaction as the amplification of the amplicon for the GOI
- Does not require standards with known concentrations

#### Calculation Methods for Relative Quantitations

- Standard Curve method ( $\Delta C_T$ )
  - Two 'standard' curves (relative control & GOI)
  - May include a 2<sup>nd</sup> normalization with an arbitrarily chosen calibrator
- Comparative  $C_T$  method  $(\Delta \Delta C_T)$ 
  - · no standards, but with amplification of a reference
  - contingent upon similar amplification efficiencies of the amplicons for GOI and reference
  - · Always relative to a calibrator sample



-  $\Delta C_T$  = const because E = const (note:  $E_A \neq E_b$  is allowed)



- Same amplicon:

• 
$$E_A = E_B \Rightarrow N_A/N_B = 2^{-\Delta CT}$$

For example: if  $\Delta C_T$  between A and B is 5 cycles, then there is  $2^{-5} = 1/32$  as much A than B.

- Different amplicons:

For example: GOI(x) and endogenous control (c):

• 
$$E_X \neq E_C \Rightarrow N_x/N_c = K (1+E_c)^{CTc} / (1+E_x)^{CTx}$$



## RQ: Mathematically

- $N_{CT} = N_0 (1+E)^{CT}$  and  $I = k N_{CT}$
- The relative Intensities of samples A and B is:
  - $I_A = k_A \cdot N_{CTA} = k_A \cdot N_{OA} (1+E_A)^{CTA}$  and
  - $I_B = k_B \cdot N_{CTB} = k_B \cdot N_{OB} (1 + E_B)^{CTB}$
- at threshold:  $I_A = I_B$  thus:  $k_A \cdot N_{CTA} = k_B \cdot N_{CTB}$
- Solving for constants yields:  $K = k_B/k_A = N_{CTA}/N_{CTB}$ ,
  - inserting  $N_{CTA} = N_{OA} (1+E_A)^{CTA}$  and  $N_{CTB} = N_{OB} (1+E_B)^{CTB}$  and rearranging we get:
- $N_{OA}/N_{OB} = K \cdot (1+E_B)^{CTB} / (1+E_A)^{CTA}$  (II)
  - The fractions of A and B expressed as percentages are:

$$A = 100 \cdot [K \cdot (1 + E_B)^{CTB} / (1 + E_A)^{CTA}] / 1 + K \cdot [(1 + E_B)^{CTB} / (1 + E_A)^{CTA}]$$


$$B = 100 \cdot [1] / 1 + K \cdot [(1 + E_B)^{CTB} / (1 + E_A)^{CTA}]$$

- Relative Standards:
  - For example: the ratio of treatment (†) vs. control (c):

$$\frac{(N_A/N_B)_t}{(N_A/N_B)_c} = K \frac{(1 + E_{Bt})^{CTBt} / (1 + E_{At})^{CTAt}}{(1 + E_{Bc})^{CTBc} / (1 + E_{Ac})^{CTAc}}$$

#### Relative Standard Method, Example A

- Two serial dilutions: one for GOI (c-myc), another one for the endogenous control (GAPDH)
- Expression profiling in brain, kidney, liver, lung





- Average replicates, then divide the average c-myc (GOI) value by the average GAPDH reference value of the corresponding samples.

- For example:

 $\frac{\langle GOI \rangle}{\langle Ref \rangle}$ 

2nd normalization: Calibrator = Brain

see slide 30 for error handling

Table 1.	Amounts of c-my	c and GAPDH in H	uman Brain, Kidney,	Liver, and Lung
Tissue	c-myc ng Total Raji RNA	GAPDH ng Total Raji RNA	c-myc <sub>N</sub> Norm. to GAPDH <sup>a</sup>	c-myc <sub>N</sub> Rel. to Brain <sup>b</sup>
Brain	0.033	0.51	Annlind	Diagratama I lagr
	0.043	0.56		Biosystems User #2 (PN 4303859)
	0.036	0.59	Bandan	12 (111 100000)
	0.043	0.53		
	0.039	0.51		
	0.040	0.52		
Average	0.039±0.004	0.54±0.034	0.07±0 008	1.0±0.12
Kidney	0.40	0.96		
	0.41	1.06		
	0.41	1.05		V
	0.39	1.07		
	0.42	1.06		
	0.43	0.96		V
Average	0.41±0.016	1.02±0.052	0.40±0 025	5.5±0.35
Liver	0.67	0.29		V
	0.66	0.28		
	0.70	0.28		
	0.76	0.29		
	0.70	0.26		
	0.68	0.27		
Average	0.70±0.036	0.28±0.013	2.49±0.173	34.2±2.37






- · normalize using an endogenous control, then
- · divide the normalized values by an arbitrarily chosen calibrator value (e.g. kidney in this example)


	GOI raw	185 raw	Normalized GOI/185	Relative Value
kidney	82	3592	0.023	1.0
liver	18351	8996	2.05	90
ovary	44	1669	0.03	1.3
spleen	1	8	0.13	5.6

- Quality of quantification using the relative standard curve method:
  - quantitative accuracy = f (standard curve)
  - · More accurate than the absolute standard method




## Relative Standard Method, Example B

- e.g. c-myc Expression Analysis in Liver, Kidney Tissues
  - GOI is c-myc, endogenous control is GAPDH,
  - · reference sample is RNA isolated from lung tissue
  - 2 Standard curves: serial dilutions of a cDNA sample generated from <u>lung</u> tissue tRNA one series is analyzed for c-myc, the other for GAPDH.




From: Applied Biosystems Documentation PN 4376785 Rev D

# SDSv2 Does the Analysis For You



## Relative Standard Method, Example C

- Relative to endogenous control AND treatment(s)
- For example: +/- TNFa induced TNFAIP3 and GAPDH



0.17 / 0.14 0.0048 / 0.13

(TNFAIP3/GAPD)<sub>treated</sub>.

(TNFAIP3/GAPD)<sub>untreated</sub>

 $\frac{(N_{A}/N_{B})_{t}}{(N_{A}/N_{B})_{c}} = \frac{(1 + E_{Bt})^{CTBt}}{(1 + E_{Bc})^{CTBc}} = \frac{(1 + E_{At})^{CTAt}}{(1 + E_{Ac})^{CTAc}}$ 

SuperArray Bioscience Corporation Newsletter 1



- Derivation of the  $\Delta\Delta C_T$  Method
  - Targets at threshold cycle  $C_T$ :  $\Rightarrow N_{CT} = N_0 \cdot (1+E)^{CT}$ 
    - For X<sub>T</sub>: number of target GOI molecules at threshold
    - and R<sub>T</sub>: number of reference molecules at threshold
    - $X_T/R_T = X_0 \cdot (1+E_x)^{CTX} / R_0 \cdot (1+E_R)^{CTR} = K_x / K_R = K$
  - If  $E_X \approx E_R =: E \Rightarrow K = X_0/R_0 \cdot (1+E)^{CTX-CTR} = X_N \cdot (1+E)^{\Delta CT}$ Whereby  $\Delta C_T = CT_X - CT_R$ , and  $X_N = X_0/R_0$ Rearranged:  $X_N = K/(1+E)^{\Delta CT}$ , or  $X_N = K \cdot (1+E)^{-\Delta CT}$  (III)
  - Another normalization of each normalized sample  $X_N$  by the  $X_N$  of a calibrator (cb) yields:

$$X_{N,Cb} = K (1+E)^{-\Delta CT} / K (1+E)^{-\Delta CT,Cb} = (1+E)^{-\Delta \Delta CT}$$

- E = const., and with N =  $X_N/X_{N,cb}$ : N =  $2^{-\Delta\Delta CT}$  (IV)
- Quality of quantification:
  - quantitative accuracy = f(amplification efficiency)
  - · Accurate and most efficient QPCR data analysis method.
  - (don't use the  $\triangle\triangle$ CT method if CV > 4%, see later)



## $\Delta\Delta C_{T}$ Method continued

- SDS v2 does it for you! Otherwise, use Excel
- Normalize GOI signals to signals of an endogenous reference (e.g. 185):  $CT_{GOI}$   $CT_{185} \Rightarrow \Delta CT_{r}$
- Normalize each  $\Delta CT_r$  value to a particular  $\Delta CT_c$  value of an assay calibrator (cb):  $\Delta CT_r$   $\Delta CT_{cb}$   $\Rightarrow \Delta \Delta CT_r$  and one  $\Delta \Delta CT_{cb}$ .
  - This is a second subtraction, and  $\Delta\Delta CT_{cb} = 0$
  - Calibrator cb may be a control treatment, or the sample with the highest  $\Delta C_{\rm T}$ r value
- The relative target number N then is  $2^{-\Delta\Delta CT}$

	GOI CT	185 <i>C</i> T	Norm. I △CT	Norm. II ΔΔCT	Ν
Е	24	14	10	-1	2
Р	20	11	9	-2	4
E+P	21	11	10	-1	2
DMSO	27	16	11	0	1

# Comparative $C_T$ Method ( $\Delta\Delta C_T$ ) Example B

- e.g. p53 Expression in Liver, Kidney, Brain Tissues
  - GOI is TP53, endogenous control is GAPDH
  - Assumption: similar amplification efficiencies ( $E_{TP53} = E_{GAPDH}$ ) ( $\Delta\Delta C_T$  validation experiment, see later)







For comparison: Relative standard method: 48 wells

From: Applied Biosystems Documentation PN 4376785 Rev D

# SDSv2 Does the Analysis For You







				Select We	ells With: - Se	lect Item - 💌		1- 4				
Show	w in Table	▼ Group By ▼		- 0 01						Expand All	15 co	ollapse A
1	Vell	Omit Flag	Sample	Target N	Task	Dyes	CT	Cr Mean	CT SD	ΔCτ ΔC	r Mean	ΔCT SE
8	Brain - C	APDH - 23.386133										
1	C7		Brain	GAPDH	UNKNOWN	FAM-NFQ	23.386133	23.427872	0.067			
8	Brain - G	SAPDH - 23.392385										
2	CB		Brain	GAPDH	UNKNOWN	FAM-NFQ	23.392385	23.427872	0.067			
8		SAPDH - 23.505096										
3	C6		Brain	GAPDH	UNKNOWN	FAM-NFQ	23.505096	23.427872	0.067			
8		P53 - 30.856344	1000000			- Commence of the Commence of						
4	C3		Brain	TP53	UNKNOWN	FAM-NFQ	30.856344	30.912079	0.049		7.484	0
		P53 - 30.93019										
5	C5	P53 - 30 949701	Brain	TP53	UNKNOWN	FAM-NFQ	30.93019	30.912079	0.049		7.484	0
	C4	753 - 30.949701	Brain	TP53	LINICATOWAL	FAM NEO	30.949701	20.04.2070	0.049		7.484	0
0	-	. Undetermined	brain	11-03	UNKNOWN	FAM: NEW	30.949701	30.912079	0.049		7.404	U
7	A4	- Ondetennmen		GAPDH	NTC	EAM-NEO.	Undetermi					
8	A5	H		GAPDH	NTC		Undetermi					
9	A6	H		GAPDH	NTC	FAM-NFQ						
8	Kidney -	GAPDH - 24.832582										
0	C1		Kidney	GAPDH	UNKNOWN	FAM-NFQ	24.832582	24.888632	0.059			
8	Kidney -	GAPDH - 24.883427										
1	B8		Kidney	GAPDH	UNKNOWN	FAM-NFQ	24.883427	24.888632	0.059			
8		GAPDH - 24.949886										
2	C2		Kidney	GAPDH	UNKNOWN	FAM-NFQ	24.949886	24.888632	0.059			

# $\Delta\Delta C_T$ Method, Example C

· siRNA Transfection

- Quantitation of % Knock-down and remaining gene expression:

Sample	Amplicon	СТ	ΔCT	ΔΔCT	
siRNA	Primer/Probe		CT(GOI) -	ΔCT(GOI) -	
Target	Target	СТ	CT(control)	ΔCT(NC)	
GOI	GOI	26.98	15.23	4.89	
GOI	18S rRNA	11.75			
NC	GOI	22.87	10.34		
NC	18S rRNA	12.53			
Percent rem	aining gene expres	sion:	2exp-ΔΔCT	$2^{-4.89} = 3.37\%$	
Percent kno	ckdown:		100 - 3.37%	96.63%	




# Validation Experiment

 $\Delta\Delta C_{T}$  Method is contingent upon  $E_{GOI} \approx E_{Ref}$ 

- The absolute value (|s|) of the slope s of log input amount (or dilutions) vs.  $\Delta C_T$  should be less than 0.1


 $E_X$  vs.  $E_R$ Efficiencies: |s| < 0.1

E max. amplification efficiency: s = -3.32



Livak and Schmittgen, 2001, Methods 25, 402-408

- Comparing important linear regression plots for QPCR:



Rainer B. Lanz, M.S., Ph.D

# What If $E_{GOI} \neq E_{ref}$ ?



 Note: Rainer does NOT recommend this method of QPCR data analysis (if you had followed all the recommendations thus far, you most likely would not have this problem now)

Relative N = 
$$\frac{(E_{x})^{\Delta CT} \times (\text{control-sample})}{(E_{R})^{\Delta CT} \times (\text{control-sample})}$$

$$= \frac{(E_{R})^{CT} \times (\text{control-sample})}{(E_{R})^{CT} \times (\text{control-sample})}$$

#### Use REST Software

- REST® (Relative Expression Software Tool)
  - Pfaffl et al. 2002. Nucl. Acids Res; 30(9): E36
  - <a href="http://www.gene-quantification.info/">http://www.gene-quantification.info/</a> then go to 'Data Analysis', 'qPCR software applications', 'REST versions', then scroll down to 'New REST software application are available:'



- √ Specificity
  - Assay design and project integration: a prerequisite
  - Determining the amplification efficiency: a prerequisite
  - Melting curve analysis: maybe (for spotting primer-dimers)
- √ Sensitivity
  - TaqMan® or SYBR®: comparable dynamic range, sensitivity
  - Efficiency
    - $E_{exp} = 10^{(-1/s)}$  -1 over a wide range of input material
    - Pearson correlation coefficient r ≥ 0.95

#### Accuracy and Reproducibility


- Replicates for intra-assay precision
- Strategy: RT = main source of variability ⇒ single cDNA pool, RT assay optimization
- Repetitions for inter-assay precision (Reproducibility)
  - not necessary (× peer reviewer's thinking)
  - Use a calibrator for inter-plate-normalizations
- Optimizing sub-optimal experiments: always E, RT rxn




- Biological Variations
  - = f{population being studied},
  - Large CV (e.g. gene expression: CV 20 to 100%)
- Process Variations
  - Random variations: common-cause errors, not affecting all samples, = f{accuracy, standard operating procedure}
    - · e.g. pipetting errors
  - Systemic variations: biasing all samples, = f{calibration, standard operating procedure}
    - · e.g. software settings in sequence detection systems
- System Variations
  - System constant, affecting all samples equally, = f{instrument accuracy}
    - Fluorescence increase I is proportional to the amount of target DNA:  $I = k \cdot R_{CT}$

## Accuracy versus Precision

- Accuracy
  - How close a measurement is to the true or actual value
- · Precision
  - How close the measured values are to each other,
  - = f{variability of the data}





Example: 4 Populations

- AppliedBiosystems TechNotes 14-4
- A, B: small system and population variability, large fold difference between the means (30-fold, ~3% CV)
- C, D: larger dispersion around the means, small fold difference between the means (1.3-fold, ~30% CV)





- Separate biological samples, same treatment, > variability of the biology + variability of the quantitation process
  - · e.g. different RNA extractions from multiple animals, ...
- Technical (Systematic) Replicates
  - Aliquots from the same source run through the quantitation process independently, > variability of the process
    - · e.g. triplicates for PCR from cDNA from one RT reaction
- How Many Replicates?
  - The greater the fold changes between the means of different populations, the fewer replicates are needed.
  - The more dispersed the population variability, the more biological replicates are needed:

Fold	Experiment	al Variation	1 (%CV) [S	STDEV/MEAN	N x100]
Difference	10%	25%	50%	75%	100%
1.5	4	7	18	38	136
2	3	4	9	16	28
3	3	3	6	10	15
5	3	3	5	7	11
10	3	3	4	6	9
	one-tailed t-t	test			

# PCR Reproducibility



- Expressed as the Standard Deviation (SD) in  $C_T$ , as the square root of the variance. The variance is

$$SD^{2} = \frac{\sum_{i=1}^{n} (C_{Ti} - \langle C_{T} \rangle)^{2}}{n-1}$$

where  $\langle$   $\textit{C}_{\text{T}}\rangle$  is the mean of the measured  $\textit{C}_{\text{T}}$ 

Use "=STDEV(number1, number2, number3, ...)" in Excel

- The relative uncertainty in the number of DNA molecules is expressed by the CV, the Coefficient of Variation, which is the ratio of the standard deviation of a distribution to its arithmetic mean ( $\langle X \rangle$ ):

$$CV = SD/\langle X \rangle$$
, or for QPCR:  $CV = SD/\langle C_T \rangle$ , or in %:

$$CV_{\%} = 100 \frac{SD}{\langle (1+E)^{-CT} \rangle}$$

where  $\langle (1+E)^{-CT} \rangle$  is the mean of  $(1+E)^{-CT}$ 

Replicate 3

=STDEV(A1:A3)

# Coefficient of Variation: Example

$$CV_{\%} = 100 \frac{SD}{\langle (1+E)^{-CT} \rangle}$$

 $0.039 / 14.561 \times 100 = 0.267\%$ 

Sample Name	Detector	Reporter	Task	Ct	Ct mean	St dev	CV on Ct (%)
Dil. 1:10	18S	VIC	Std	14.589	14.561	0.039	0.267
Dil. 1:10	18S	VIC	Std	14.577			
Dil. 1:10	18S	VIC	Std	14.517			
Dil. 1:100	18S	VIC	Std	18.115	18.148	0.092	0.508
Dil. 1:100	18S	VIC	Std	18.252			
Dil. 1:100	18S	VIC	Std	18.077			
Dil. 1:1000	18S	VIC	Std	22.051	21.973	0.085	0.387
Dil. 1:1000	18S	VIC	Std	21.882			
Dil. 1:1000	18S	VIC	Std	21.882			
Dil. 1:10000	18S	VIC	Std	25.462	25.365	0.088	0.348
Dil. 1:10000	18S	VIC	Std	25.291			
Dil. 1:10000	18S	VIC	Std	25.341			
Dil. 1:100000	18S	VIC	Std	29.261	29.244	0.024	0.083
Dil. 1:100000	18S	VIC	Std	29.216			
Dil. 1:100000	18S	VIC	Std	29.255			

# Calculating Standard Deviations

SD = f{QPCR Data Analysis Method}

#### For the Standard Curve Method:

- The  $SD_Q$  for the normalized (GOI/Ref) quotient Q is calculated using:  $SD_Q = CV_Q \cdot \langle X \rangle$ , with

$$CV_Q = (CV_{GOI}^2 + CV_{Ref}^2)^{1/2}$$

#### For the Comparative Method:

- The  $SD_S$  for the difference (of  $\Delta C_T$  values) is based on the SD of the GOI <u>AND</u> SD of the reference values:  $SD_S = (SD_{GOI}^2 + SD_{Ref}^2)^{1/2}$
- The SD of the  $\Delta\Delta CT_r$  is the same as the SD<sub>S</sub>.

OK, now let's put everything together - Error Handling for the relative quantification in practice:

a) Standard curve method, b) Comparative method

# a) Error Handling for the Standard Curve Method

•  $N = (N_{GOI}/N_{Ref}) \times (CV_{GOI}^2 + CV_{Ref}^2)^{1/2}$ 

- The average values of the GOI replicates is divided by the average values of the reference samples ( $N_{GOI}/N_{Ref}$  =:Q). The  $SD_Q$  of the quotient is calculated using:

$$CV_Q = SD_Q/\langle X \rangle = (CV_{GOI}^2 + CV_{Ref}^2)^{1/2}$$
 (V)

i.e., calculate the SDs for the replicates of GOI and Ref first, then their individual CVs. Use these CVs to calculate the CV for the normalized (GOI/Ref) using (V). Obtain the SD $_Q$  of the quotient using SD $_Q$  =  $CV_Q \cdot \langle X \rangle$ 

	GOI mean	GOI SD	GOI CV	Ref mean	Ref SD	Ref CV	GOI/ Ref	$CV_Q$	SD <sub>Q</sub>
Brain&	0.039	0.004	0.004/ 0.039= 0.1026	0.54	0.034	0.034/ 0.54= 0.063	0.039/ 0.54 = 0.072	0.12*	0.12 · 0.072= 0.009
Kidney <sup>&amp;</sup>	0.41	0.016	0.016/ 0.41= 0.039	1.02	0.052	0.052/ 1.02= 0.051	0.41/ 1.02 = 0.402	0.06#	0.06 · 0.402= 0.026

# b) Error Handling for the Comparative $C_T$ Method

- $N = 2 \Delta \Delta CT \left(2 \Delta \Delta CT SDs 2 \Delta \Delta CT + SDs\right)$ 
  - Calculate mean, SD and CV for replicate  $C_T$  values of GOI and Ref, reject >4%CV.
  - Determine  $\Delta CT_r = \langle CT_{GOI} \rangle$   $\langle CT_{185} \rangle$ . The SD of the difference (SD<sub>S</sub>) is based on the SD of the GOI and the SD of the reference values:  $SD_S = (SD_{GOI}^2 + SD_{Ref}^2)^{1/2}$
  - Normalize each  $\Delta CT_r$  value to a particular  $\Delta CT_c$  value of an assay calibrator (cb):  $\Delta \Delta CT_r = \Delta CT_r \Delta CT_{cb.}$  The SD of the  $\Delta \Delta CT_r$  is the <u>same</u> as the SD<sub>S</sub> (SD<sub> $\Delta\Delta CTr$ </sub> = SD<sub> $\Delta CTr$ </sub>).
  - The final relative values (fold induction) are  $2^{-\Delta \Delta CT}$  with  $\Delta \Delta CT_r$   $SD_s$  and  $\Delta \Delta CT_r$ +  $SD_s$

**Table 3.** Relative Quantitation Using the Comparative C<sub>T</sub> Method

Tissue	c-myc Average C <sub>T</sub>	GAPDH Average C <sub>T</sub>	ΔC <sub>T</sub> c-myc-GAPDH <sup>a</sup>	ΔΔC <sub>T</sub> ΔC <sub>T</sub> –ΔC <sub>T, Brain</sub> b	c-myc <sub>N</sub> Rel. to Brain <sup>c</sup>
Brain	30.49±0.15	23.63±0.09	6.86±0.17	0.00±0.17	1.0 (0.9–1.1)
Kidney	27.03±0.06	22.66±0.08	4.37±0.10	-2.50±0.10	5.6 (5.3–6.0)

a, b:  $SQRT[0.15^2 + 0.09^2] = 0.175$ , c:  $2^{0.0+0.175} = 1.1$ ,  $2^{0.0-0.175} = 0.88$ 

a, b:  $SQRT[0.06^2 + 0.08^2] = 0.100$ , c:  $2^{2.5+0.100} = 6.06$ ,  $2^{2.5-0.100} = 5.28$ 

## Remarks to Quantitative Precision

#### **Implications**

- The calculations of precision given above have been questioned in some peer-reviewed publications.
- Replicate standard curves may produce potentially large inter-curve variations.
- In general, the intra-assay variation of 10-20% and a mean inter-assay variation of 15-30% on molecule basis is realistic over the wide dynamic range (of over a billion fold range).
  - Variability is highest at >10<sup>7</sup> and <10<sup>2</sup> template copy ranges
    - Cut-off value: cycle 35, i.e. disregard  $C_T$  values for cycle numbers 36 and higher.
- For the threshold methods, the precision is dependent on the proper setting of the threshold, which itself is dependent on proper base line settings.



Baseline Threshold



# A Recent User Submission

A	В	С	D	Е	F	G	Н		J	K	L	M
GOI	REF	AV GOI	AV Ref	STDEV GOI	STDEV REF	CV on CT GOI	CV on CT ref	<b>ӘСТ</b>	SD ∂CT	ааст	SD ∂∂CT	Result
21.82	6.89	The second second second second										
23.62	8.13											
21.47	7.35											
23.14	8.53	22.51	7.73	1.03	0.74	4.58	9.60	14.79	1.27	3.51	1.27	4.71
												27.37
22.42	7.81											
23.01	7.79											
23.21	8											
22.41	7.05	22.76	7.66	0.41	0.42	1.80	5.47	15.10	0.586	3.82	0.59	9.39
												21.16
22.48	8.03											
20.7	7.36											
20.56	7.63											
20.66	7.58	21.10	7.65	0.92	0.28	4.37	3.65	13.45	0.963	2.17	0.96	2.30
												8.76
19.3	7.92											
19.11	7.97											
18.94	7.89											
19.42	7.86	19.19	7.91	0.21	0.05	1.10	0.59	11.28	0.216	0.00	0.22	0.86
												1.16


Rainer B. Lanz, M.S., Ph.D.

## Integrated Genomics - The Future?

• Real-Time StatMiner<sup>TM</sup>




- http://www.integromics.com/StatMiner.php



# Optimizing Primer Concentrations


- Primer Optimization Matrix
  - Maximize  $\Delta Rn$ :

		10:	F 447						
Reverse	Forward Primer [nM]								
Primer [nM]	50	300	900						
50	50/50	300/50	900/50						
300	50/300	300/300	900/300						
900	50/900	300/900	900/900						



Suggested conc.:

- · 900nM for TaqMan
- · 50nM for SYBR Green




# Optimizing Probe Concentrations

- Secondary to Primer Optimization
  - Maximize  $\Delta Rn$ :


Primer [nM]	Probe [nM]
100/900	50
100/900	125
100/900	250
100/900	500


- Suggested conc.:
  - · 250nM



# Optimizing Genotyping Experiments

- Scattering of Data Points / Diffuse Clusters
  - Low DNA concentrations
  - Suggested: > 1ng (relatively high)





# Multiplexing

Primer-Limited Assays

- ABI Vic® reporter dyes are primer limited, allowing multiplexing of TaqMan® endogenous controls with

GOI quantitation.

- Extensive assay optimization


Normal probe levels: 250nM

- Suggested primer conc.:

50nM or less


- Determine plateau region:

CT values are constant





- Questions a PI should ask when presented with QPCR data:
  - How does this assay integrate with the project?
    - 1 primer pair per question! (1pppq)
  - Did you use a 'One-step' kit?
    - If "Yes" -> deny the assay!
  - What assay was used? commercial or custom design?
  - What chemistry was used? Why?
    - If TaqMan: MGB or conventional probe?
  - What is the amplification efficiency (E) for this amplicon?
    - Show me the 'Primer validation' experiment!
  - How do the amplification plots look like?
    - · How did you adjust the baseline, the threshold?
  - How many times did you measure this result? How many runs were necessary to get to this result?
  - What method of data evaluation did you use?
    - If  $\triangle \triangle C_T$ : show me the validation experiment.
  - How many replicates were used for the measurements?
  - Are any  $C_{T}$  values larger than 35?
  - What did you do for error handling?





#### Selected References

- Bookout A. and Mangelsdorf D. (2003), Nuclear Receptor Signaling 1, e012,
- Ditto, Supplementary File 1: QPCR Protocols and Worksheets (http://nursa.org/ejournal/published/01012/nrs01012.sp1.pdf)
- Applied Biosystems. (1997) Relative Quantitation Of Gene Expression: ABI PRISM 7700 Sequence Detection System: User Bulletin #2: Rev B. (AppliedBiosystems PN 4303859)
- Collins M.L et al (1995), Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal. Biochem. 226: 120-129
- Higuchi, R. et al. (1992). Simultaneous amplification and detection of specific DNA sequences. Biotechnology 10:413-417.
- Higuchi, R. et al. (1993). Kinetic PCR: Real time monitoring of DNA amplification reactions. Biotechnology 11:1026-1030.
- Kwok, S. and Higuchi, R. (1989) Avoiding false positive with PCR. Nature 339:237-238.
- Livak, K.J. and Schmittgen, T.D. (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the  $2^{-\Delta\Delta CT}$  Method. Melthods 25:402-408.
- Livak, K.J. et al. (1995) Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl.4:357-62
- Morrison, T.B. et al. (1998) Quantification of Low-Copy Transcripts by Continuous SYBR Green I Monitoring During Amplification. Biotechniques 24(6):954-962.
- Suzuki T. et al. (2000) Control Selection for RNA Quantification. Biotechniques 29(2):332-337.
- Whittwer C.T. et al. (1997) Continuous Fluorescence Monitoring of Rapid Cycle DNA Amplification. Biotechniques 22(1):130-138
- Pfaffl et al. (2002) Nucl. Acids Res; 30(9): E36